Tibet Aim Pharm Inc
SZSE:002826
Intrinsic Value
Tibet Aim Pharm., Inc. engages in the research and development, production, and sale of chemical drugs, and Chinese medicines. [ Read More ]
The intrinsic value of one
Tibet Aim Pharm Inc
stock under the Base Case scenario is
8.55
CNY.
Compared to the current market price of 9.19 CNY,
Tibet Aim Pharm Inc
is
Overvalued by 7%.
Tibet Aim Pharm Inc's market capitalization is 1.8B CNY.
Tibet Aim Pharm Inc stock price is 9.19 CNY.
Tibet Aim Pharm Inc stock (8.55 CNY) is 7% less than its price (9.19 CNY).
Tibet Aim Pharm Inc stock (7.33 CNY) is 20% less than its price (9.19 CNY). Open DCF Valuation
Tibet Aim Pharm Inc stock price (9.19 CNY) is 6% less than its Relative Value (9.77 CNY). Open Relative Valuation
Tibet Aim Pharm Inc has upside potential of 31% compared to the average analyst price target.
Open Wall St Estimates
Tibet Aim Pharm Inc's Revenue has grown by 1% over the past 12 months.
Tibet Aim Pharm Inc's ROE (Return on Equity) has increased in the last 3 years from 6% to 6%.
Tibet Aim Pharm Inc's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
Tibet Aim Pharm Inc's ROIC (Return on Invested Capital) has increased in the last 3 years from 6% to 8%.
Tibet Aim Pharm Inc's ROE (Return on Equity) for the past 12 months is positive and is equal to 6%.
Tibet Aim Pharm Inc has positive Operating Income for the last twelve months.
Tibet Aim Pharm Inc has positive Net Income for the last twelve months.
Tibet Aim Pharm Inc has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
Tibet Aim Pharm Inc's Revenue has been growing by 10% per year for the last 3 years.
Tibet Aim Pharm Inc has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
Tibet Aim Pharm Inc has positive Free Cash Flow for the last twelve months.
Tibet Aim Pharm Inc has positive Gross Profit for the last twelve months.
Tibet Aim Pharm Inc's short-term assets (520m CNY) exceed its short-term liabilties (216m CNY).
Tibet Aim Pharm Inc's D/E (Debt to Equity) is very low and is equal to 0.01.
Tibet Aim Pharm Inc's long-term assets (984m CNY) exceed its long-term liabilties (230m CNY).
Tibet Aim Pharm Inc has negative Net Debt. This means that the company has more cash and short-term investments (298m CNY) than debt (10m CNY).
Tibet Aim Pharm Inc's Altman Z-Score is very high and is equal to 7.21.
Valuation Backtest
Tibet Aim Pharm Inc
Run backtest to discover the historical profit from buying and selling
Tibet Aim Pharm Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Tibet Aim Pharm Inc
Balance Sheet Decomposition
Tibet Aim Pharm Inc
| Current Assets | 519.8m |
| Cash & Short-Term Investments | 297.6m |
| Receivables | 151.5m |
| Other Current Assets | 70.7m |
| Non-Current Assets | 464.1m |
| Long-Term Investments | 42.5m |
| PP&E | 353.2m |
| Intangibles | 63.3m |
| Other Non-Current Assets | 5.2m |
| Current Liabilities | 216.3m |
| Accounts Payable | 148.8m |
| Accrued Liabilities | 7.2m |
| Short-Term Debt | 10m |
| Other Current Liabilities | 50.3m |
| Non-Current Liabilities | 13.9m |
| Other Non-Current Liabilities | 13.9m |
Earnings Waterfall
Tibet Aim Pharm Inc
|
Revenue
|
803.3m
CNY
|
|
Cost of Revenue
|
-437m
CNY
|
|
Gross Profit
|
366.3m
CNY
|
|
Operating Expenses
|
-312m
CNY
|
|
Operating Income
|
54.3m
CNY
|
|
Other Expenses
|
-7.6m
CNY
|
|
Net Income
|
46.8m
CNY
|
Free Cash Flow Analysis
Tibet Aim Pharm Inc
Profitability Score
Profitability Due Diligence
Tibet Aim Pharm Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Tibet Aim Pharm Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Tibet Aim Pharm Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
Tibet Aim Pharm Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Tibet Aim Pharm Inc
According to Wall Street analysts, the average 1-year price target for
Tibet Aim Pharm Inc
is 12 CNY
.
Shareholder Return
Price
Tibet Aim Pharm Inc
| Average Annual Return | 3.32% |
| Standard Deviation of Annual Returns | 10.35% |
| Max Drawdown | -62% |
| Market Capitalization | 1.8B CNY |
| Shares Outstanding | 189 489 500 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Tibet Aim Pharm Inc
Country
Industry
Market Cap
Dividend Yield
Description
Tibet Aim Pharm., Inc. engages in the research and development, production, and sale of chemical drugs, and Chinese medicines. The company is headquartered in Chengdu, Sichuan and currently employs 430 full-time employees. The company went IPO on 2016-12-09. The Company’s products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Tibet Aim Pharm Inc
stock under the Base Case scenario is
8.55
CNY.
Compared to the current market price of 9.19 CNY,
Tibet Aim Pharm Inc
is
Overvalued by 7%.
You don't have any saved screeners yet
